Zenas Biopharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its experimental injection therapy, obexelimab, for immunoglobulin G4-related disease (IgG4-RD). “Our obexelimab [biologics license application] submission brings us one step closer to our goal of delivering this…
A new imaging technique shows promise for assessing disease activity and organ involvement in immunoglobulin G4-related disease (IgG4-RD). Compared with biopsy results, the [18F]FAPI PET/CT scan was 100% accurate in detecting lesions in various organs, including the lung, liver, muscles, pancreas, and kidney. The researchers developed a disease activity…
Zenas Biopharma says it’s on track to submit applications this year in the U.S. and the European Union seeking approval of its experimental injection therapy obexelimab for treating immunoglobulin G4-related disease (IgG4-RD). In fact, the developer noted that it intends to file a biologics license application to the…
Get regular updates to your inbox.
